CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma
Sponsor: Bristol-Myers Squibb
Terminated
Business Decision
Other terminated trials from Bristol-Myers Squibb
Other Advanced Melanoma trials with similar outcome
Listed as NCT04695977, this PHASE2/PHASE3 trial focuses on Advanced Melanoma and Melanoma and remains terminated or withdrawn. Sponsored by Bristol-Myers Squibb, it has been updated 18 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
18 versions recorded-
Oct 2025 — Present [monthly]
Terminated PHASE2/PHASE3
-
Nov 2024 — Oct 2025 [monthly]
Terminated PHASE2/PHASE3
Status: Completed → Terminated
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE2/PHASE3
Status: Active Not Recruiting → Completed
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2_PHASE3
▶ Show 13 earlier versions
-
Feb 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Sep 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE2_PHASE3
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2022 — Apr 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2021 — Dec 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2021 — Sep 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Regeneron Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .